AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AROVELLA THERAPEUTICS LTD

0.062

0.000

Volume:793.45K

Turnover:49.18K

Market Cap:74.94M

PE:-10.69

High:0.063

Open:0.062

Low:0.061

Close:0.062

52wk High:0.125

52wk Low:0.058

Shares:1.21B

Float Shares:895.86M

Volume Ratio:1.14

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.006

EPS(LYR):-0.006

ROE:-40.41%

ROA:-23.62%

PB:5.30

PE(LYR):-10.69

Loading ...

Overview Company News Filings

Arovella Therapeutics Ltd-Letter From Managing Director and CEO

THOMSON REUTERS

Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate

MT Newswires Live

BRIEF-Arovella Therapeutics Says IND For Ala-101 Accepted By FDA

Arovella Therapeutics Ltd - Ind for Ala-101 Accepted by U.s.FDA

THOMSON REUTERS

BRIEF-Arovella Therapeutics Appoints Lachie Mallia As CFO

Arovella Therapeutics Ltd-Company Secretary/CFO Appointment/Resignation

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/stock/ALA.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ALA.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","market":"AU","secType":"STK","nameCN":"AROVELLA THERAPEUTICS LTD","latestPrice":0.062,"timestamp":1787724720000,"preClose":0.062,"halted":0,"volume":793451,"delay":0,"changeRate":0,"nameEN":"AROVELLA THERAPEUTICS LTD","floatShares":895858885,"shares":1208783672,"eps":-0.0058,"marketStatus":"Closed","change":0,"latestTime":"08-26 16:12:00 AEST","open":0.062,"high":0.063,"low":0.061,"amount":49177,"amplitude":0.032258,"askPrice":0.064,"askSize":188000,"bidPrice":0.061,"bidSize":26628,"shortable":3,"etf":0,"ttmEps":-0.0058,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787788800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.062,"openAndCloseTimeList":[[1787702400000,1787724000000]],"volumeRatio":1.144591,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ALA.AU","preClose":0.065,"auctionPrice":0.065,"auctionVolume":50000,"auction":3,"marketStatus":"盘后竞价","timestamp":1787551694778}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ALA.AU\",,,,,undefined,":{"symbol":"ALA.AU","floatShares":895858885,"roa":"-23.62%","roe":"-40.41%","lyrEps":-0.0058,"volumeRatio":1.144591,"shares":1208783672,"dividePrice":0,"high":0.063,"amplitude":0.032258,"preClose":0.062,"low":0.061,"week52Low":0.058,"pbRate":"5.30","psRate":"17.44","week52High":0.125,"institutionHeld":0,"latestPrice":0.062,"committee":-0.751868,"eps":-0.0058,"divideRate":0,"volume":793451,"delay":0,"ttmEps":-0.0058,"open":0.062,"prevYearClose":0.093,"prevWeekClose":0.065,"prevMonthClose":0.06,"prevQuarterClose":0.062,"fiveDayClose":0.063,"twentyDayClose":0.063,"sixtyDayClose":0.071},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALA.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALA.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALA.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609165883","title":"Arovella Therapeutics Ltd-Letter From Managing Director and CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2609165883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609165883?lang=en_us&edition=fundamental","pubTime":"2026-02-05 05:42","pubTimestamp":1770241363,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260204:nTUE35N0XM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607977190","title":"Arovella Therapeutics Says FDA Accepts Investigational New Drug Application for Blood Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2607977190","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607977190?lang=en_us&edition=fundamental","pubTime":"2026-01-29 12:20","pubTimestamp":1769660439,"startTime":"0","endTime":"0","summary":"Arovella Therapeutics (ASX:ALA) said the US Food and Drug Administration (FDA) accepted its investigational new drug application for its ALA-101 drug candidate to commence first-in-human clinical tria","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","ALA.AU","LENZ","BK4539","BK4139","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607209517","title":"BRIEF-Arovella Therapeutics Says IND For Ala-101 Accepted By FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2607209517","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607209517?lang=en_us&edition=fundamental","pubTime":"2026-01-29 09:25","pubTimestamp":1769649914,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Says IND For Ala-101 Accepted By FDAJan 29 (Reuters) - Arovella Therapeutics ALA.AX:IND FOR ALA-101 ACCEPTED BY U.S.FDAFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nFWN3YT16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607093725","title":"Arovella Therapeutics Ltd - Ind for Ala-101 Accepted by U.s.FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2607093725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607093725?lang=en_us&edition=fundamental","pubTime":"2026-01-29 06:11","pubTimestamp":1769638314,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605320664","title":"BRIEF-Arovella Therapeutics Appoints Lachie Mallia As CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605320664","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605320664?lang=en_us&edition=fundamental","pubTime":"2026-01-22 08:50","pubTimestamp":1769043049,"startTime":"0","endTime":"0","summary":"BRIEF-Arovella Therapeutics Appoints Lachie Mallia As CFOJan 22 (Reuters) - Arovella Therapeutics Ltd ALA.AX:COMPANY SECRETARY/CFO APPOINTMENT/RESIGNATIONAPPOINTS LACHIE MALLIA AS CFOFurther company coverage: ALA.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUE7GGP57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALA.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605743375","title":"Arovella Therapeutics Ltd-Company Secretary/CFO Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2605743375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605743375?lang=en_us&edition=fundamental","pubTime":"2026-01-22 05:32","pubTimestamp":1769031124,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nTUE7GGP57:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","ALA.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":26,"code":"91000000","status":"200"}]}}